GlassScriptPhysician profile
Jasmine Baez
NPI 1326495920
$9,700.57
in general payments reported to CMS, 2019-2025
40 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $942 · 2021: $1,126 · 2022: $1,098 · 2023: $1,686 · 2024: $1,977 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,130 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.07 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,352.91 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $1,333.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $764.32 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.49 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.37 | 2019-2025 | Jardiance |
| Amgen INC. | $576.86 | 2020-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $576.18 | 2021-2025 | Qulipta |
| Glaxosmithkline, LLC. | $568.45 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $426.57 | 2021-2025 | Korlym |
| Pfizer INC. | $352.02 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $327.95 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $300.30 | 2019-2022 | |
| Lilly USA, LLC | $269.34 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $210.71 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $157.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $153.06 | 2019-2023 | Injectafer |
| Dexcom, INC. | $140.51 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $126.71 | 2023-2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $85.29 | 2024-2025 | Heplisav-B |
| Mylan Specialty L.P. | $84.75 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $77.41 | 2019-2021 | |
| Bausch Health US, LLC | $72.84 | 2021-2023 | Aplenzin, Wellbutrin |
| Insightec,INC | $72.77 | 2025 | Exablate |
| Seqirus USA INC | $59.57 | 2022-2025 | Fluad Quadrivalent, Flucelvax, Fluad |
| Vanda Pharmaceuticals INC. | $52.55 | 2025 | Fanapt |
| Esperion Therapeutics, INC. | $45.66 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $44.84 | 2024-2025 | |
| Renalytix Ai, INC. | $35.68 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Currax Pharmaceuticals LLC | $30.72 | 2022-2025 | Contrave |
| Sanofi Pasteur INC. | $30.67 | 2019-2022 | |
| Topcon Healthcare Solutions, INC. | $29.48 | 2020 | |
| Philips North America LLC | $23.75 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2025 | Recorlev |
| Phadia US INC. | $18.35 | 2025 | Immunocap |
| Recordati_rare_diseases_inc. | $16.18 | 2025 | Isturisa |
| Gilead Sciences, INC. | $14.49 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $13.72 | 2021 | |
| Genentech USA, INC. | $12.98 | 2019 | |
| Cequr Corporation | $12.91 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Baez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.